Incidence of cardiac events slightly higher with trastuzumab
the ONA take:
The cumulative incidence of cardiac events (CE) at 6 years was slightly higher in patients with HER2-positive early breast cancer receiving trastuzumab, a new study published online ahead of print in the Journal of Clinical Oncology has shown.
For the study, patients received adjuvant doxorubicin plus cyclophosphamide followed by either weekly paclitaxel (arm A), paclitaxel then trastuzumab (arm B), or paclitaxel plus trastuzumab followed by trastuzumab alone (arm C).
Results showed that the cumulative incidence of cardiac events was 0.6% in arm A, 2.8% in arm B, and 3.4% in arm C.
Researchers found that left ventricular ejection fraction (LVEF) recovered in the majority of patients that developed congestive heart failure.
The study also demonstrated that age 60 years or older, LVEF <65% at baseline, and use of antihypertensive medications were associated with an increased risk of cardiac events in patients receiving trastuzumab.
“The cumulative incidence of CE at 6 years was slightly higher with the addition of trastuzumab; however, the late development of CE is infrequent,” the authors conclude. “Trastuzumab (in the context of anthracycline- and taxane-based therapy) continues to have a favorable benefit-risk ratio.”
The cumulative incidence of cardiac events (CE) at 6 years was slightly higher in patients with HER2-positive early breast cancer receiving trastuzumab.
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Baseline PSA Levels in Midlife Could Predict Risk of Lethal Prostate Cancer
- Community Breast Navigation Program Improved Breast Screening Rates in Underserved African American and Latino Women
- Live-streamed Videos Address End-of-Life Planning, Decision-making
- Metastatic Disease Linked to Patients Reporting Diminished QoL
- History of Bilateral Salpingo-oophorectomy, Hormone Replacement Therapy Are Predictive of Breast Density at Cancer Diagnosis
- Mammographically Occult Contralateral Breast Cancer Detection is Effective With Preoperative MRI
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|